A fermented soy permeate improves the skeletal muscle glucose level without restoring the glycogen content in streptozotocin-induced diabetic rats.
Exercise is essential into the therapeutic management of diabetic patients, but their level of exercise tolerance is lowered due to alterations of glucose metabolism. As soy isoflavones have been shown to improve glucose metabolism, this study aimed to assess the effects of a dietary supplement containing soy isoflavones and alpha-galactooligosaccharides on muscular glucose, glycogen synthase (GSase), and glycogen content in a type 1 diabetic animal model. The dietary supplement tested was a patented compound, Fermented Soy Permeate (FSP), developed by the French Company Sojasun Technologies. Forty male Wistar rats were randomly assigned to control or diabetic groups (streptozotocin, 45 mg/kg). Each group was then divided into placebo or FSP-supplemented groups. Both groups received by oral gavage, respectively, water or diluted FSP (0.1 g/day), daily for a period of 3 weeks. At the end of the protocol, glycemia was noticed after a 24-h fasting period. Glucose, total GSase, and the glycogen content were determined in the skeletal muscle (gastrocnemius). Diabetic animals showed a higher blood glucose concentration, but a lower glucose and glycogen muscle content than controls. Three weeks of FSP consumption allowed to restore the muscle glucose concentration, but failed to reduce glycemia and to normalize the glycogen content in diabetic rats. Furthermore, the glycogen content was increased in FSP-supplemented controls compared to placebo controls. Our results demonstrated that diabetic rats exhibited a depleted muscle glycogen content (-25%). FSP-supplementation normalized the muscle glucose level without restoring the glycogen content in diabetic rats. However, it succeeded to increase it in the control group (+20%).
Laboratory Movement, Sport and Health Sciences-M2S, University of Rennes 2 and École Normale Supérieure-ENS de Cachan, Rennes, France. ludivine.malarde@gmail.com
Ludivine
L
Malardé
Sophie
S
Vincent
Luz
L
Lefeuvre-Orfila
Théo
T
Efstathiou
Carole
C
Groussard
Arlette
A
Gratas-Delamarche
D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000178:diet therapy* / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000178:diet therapy* / Q000378:metabolism; D019587:Dietary Supplements / Q000032:analysis; D005285:Fermentation; D005947:Glucose / Q000378:metabolism*; D006003:Glycogen / Q000378:metabolism*; D006801:Humans; D007529:Isoflavones / Q000008:administration & dosage / Q000378:metabolism; D008297:Male; D018482:Muscle, Skeletal / Q000378:metabolism*; D010936:Plant Extracts / Q000008:administration & dosage* / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013025:Glycine max / Q000378:metabolism* / Q000382:microbiology; D014312:Trisaccharides / Q000008:administration & dosage / Q000378:metabolism
D007529:Isoflavones; D010936:Plant Extracts; D014312:Trisaccharides; D006003:Glycogen; D005947:Glucose